Fresenius SE & Co KGaA (FRA:FRE) received a €80.00 ($95.24) target price from analysts at Independent Research in a research note issued on Thursday. The brokerage presently has a “buy” rating on the stock. Independent Research’s price target would indicate a potential upside of 23.61% from the stock’s previous close.

A number of other research firms have also issued reports on FRE. Citigroup set a €83.00 ($98.81) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Thursday, October 19th. Goldman Sachs Group set a €78.00 ($92.86) price target on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Tuesday, October 31st. Warburg Research set a €80.00 ($95.24) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Thursday, December 21st. Bank of America set a €75.00 ($89.29) price target on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Monday, November 6th. Finally, Kepler Capital Markets set a €63.00 ($75.00) price target on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Tuesday, November 28th. Six research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Fresenius SE & Co KGaA presently has a consensus rating of “Buy” and an average target price of €79.60 ($94.76).

Shares of Fresenius SE & Co KGaA (FRA FRE) opened at €64.72 ($77.05) on Thursday. Fresenius SE & Co KGaA has a 1-year low of €60.16 ($71.62) and a 1-year high of €80.00 ($95.24). The stock has a market cap of $35,540.00 and a P/E ratio of 20.61.

ILLEGAL ACTIVITY WARNING: “Fresenius SE & Co KGaA (FRE) Given a €80.00 Price Target at Independent Research” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/04/fresenius-se-80-00-price-target-at-independent-research.html.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.